IDEMIA
14.12.2020 10:32:12 CET | Business Wire | Press release
IDEMIA:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005279/en/
Security and convenience at the heart of the Icelandic project
By 2022, new EU-EES regulations will require that biometric data, including face and fingerprints, of Third Country Nationals (TCNs) be captured and identified at the Schengen Area’s external borders. This will affect border check processes for all Schengen Member States.
With 20%-a-year air traffic growth (prior to COVID-19), Iceland planned to implement a program to manage increased passenger flows primarily in Iceland’s main international airport Keflavik, where 95% of the country’s largely non EU arriving and exiting passengers pass, and also in the country’s 30 seaports defined as external sea border crossing points. The new border management systems and equipment will also contribute to inland control within the Schengen Area.
Iceland, innovation partner in border management
IDEMIA will leverage its best-in-class biometric and border control expertise to uphold and upgrade Iceland’s border security. Meanwhile, this cutting-edge technology will contribute to more secured external borders and optimize the passenger flow by the use of the newest technology in border management.
This new border management system, based on IDEMIA’s Augmented Borders™ solution, will be compliant with EU-EES regulations. IDEMIA will also equip Icelandic border crossing points with its TravelKiosk™ EU-EES, the latest generation of user-centric multi-biometric border self-service kiosks . Also including automated TraveLane™ eGates, the entire system will boost throughput and convenience of passengers as they go through border controls. Lastly, to complete this end-to-end solution, IDEMIA will ensure that operator-manned counters, mobile solutions and tracking systems are set up to fit the requirements of the Icelandic Police with a view to shortening response times and improving coordination.
“The National Commissioner of the Icelandic Police, the Metropolitan Police and Sudurnes District police have from early 2019 been working on the implementation of EES in Iceland in close cooperation with Isavia. The procurement procedure started in September 2019 and today we have reached an important milestone by selecting IDEMIA as the supplier and future partner for the implementation of EES in Iceland. The police and Isavia place a high expectation to the collaboration with IDEMIA in the development of solutions that will improve border security and the traveler experience,” said Jón Pétur Jónsson , Chief Superintendent, at the National Commissioner of the Icelandic Police.
“ Isavia is truly excited about this co-operation with IDEMIA and the Icelandic Police. This is an important step in improving the performance and customer experience of the convenient and easy hub connection between Europe and North America, ” says Guðmundur Daði Rúnarsson , Chief Commercial and Airport Development Officer at Isavia. “ The Entry Exit system will affect all airports with traffic crossing external borders. Isavia is confident that implementing IDEMIA’s self service solutions in co-operation with the border police, will result in a more secure and efficient border crossing point, giving Keflavik the potential to grow even further in its Hub operation. ”
“IDEMIA is proud to accompany Iceland as one of the first countries of the Schengen Area to transform its border control system to comply with the European Entry/Exit System. We are determined to provide a comprehensive set of multi-biometric solutions that will give the assurance of a future-proof program, making Iceland our innovation partner in the implementation of the EU-EES. Our advanced border management solutions, based on a 40-year relationship with governments, will offer a better user experience by interactively adapting the border process per traveler category, while ensuring maximum security,” said Philippe Barreau , Executive Vice President for Public Security & Identity activities at IDEMIA.
As world leader in government identity and police biometric systems, IDEMIA brings to the table its cutting-edge technology and know-how so that personal identity is checked in the most secure way.
Recently, IDEMIA, in partnership with Sopra Steria, was selected to roll out the shared Biometric Matching System - the new European automated multi-biometric identification system for foreign nationals hosted by EU agency eu-LISA. Having partnered with EU institutions for many years and installed border control systems in more than 23 countries, IDEMIA’s comprehensive package meets the complex requirements of border control authorities, topped off by state-of-the-art technology.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com or follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
